2 documents found, page 1 of 1
CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells
Mensurado, Sofia; Condeço, Carolina; Sánchez-Martínez, Diego; Shirley, Sara; Coelho, Rui; Tirado, Néstor; Vinyoles, Meritxell; Blanco Dominguez, RafaelRelapsed or refractory acute myeloid leukemia (AML) remains a major therapeutic challenge. We have recently developed a Vδ1+ γδ T cell-based product for adoptive immunotherapy, named Delta One T (DOT) cells, and demonstrated their cytolytic capacity to eliminate AML cell lines and primary blasts in vitro and in vivo. However, the molecular mechanisms responsible for the broad DOT-cell recognition of AML cells r...
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cell...
Sánchez Martínez, Diego; Tirado, Néstor; Mensurado, Sofia; Martínez-Moreno, Alba; Romecín, Paola; Gutiérrez Agüera, Francisco; Correia, Daniel V.Background: Chimeric antigen receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory hematological tumors, showing impressive complete remission rates. However, around 50% of the patients relapse before 1-year post-treatment. T-cell 'fitness' is critical to prolong CAR-T persistence and activity. Allogeneic T cells from healthy donors are less dysfunctional or exhausted than autol...